Virtual-Strategy Magazine (press release) SAN DIEGO, June 12, 2013 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX), a biopharmaceutical company focused on the discovery, development and commercialization of antibiotics for serious infections, today announced the publication of ... 更多 »
Examiner.com A change in national treatment guidelines in 2010 to prolong the use of cephalosporins, replacing cefixime with high doses of ceftriaxone plus azithromycin before resistance reached the 5 percent threshold. Resistance to cefixime has reached a level ... and more »
Healio "Based on our findings, we hope that clinicians will consider prescribing antibiotics judiciously for their patients, and carefully evaluate if the patient has a true allergic reaction before prescribing alternative agents ," study researcher Lilian M ...
